The Pharmaceutical company Lilly has announced that there are two drugs being developed that could change how type 2 diabetes is treated.

Both drugs are injectable glucagon like peptides or amino acids and are designed to be used once a week.

The first drug Dulaglutide has been shown in five studies ranging from 52 to 108 weeks to reduce A1c levels more successfully than comparable drugs like Byetta, Januvia and Metformin.

It has also been found that this new drug works just as well as insulin to control blood glucose levels.

Lilly is wanting to submit data from these studies to the U.S. regulatory authorities in 2013 seeking marketing approval for the new drug.

The second drug is TT-401. It showed a significant improvement in blood glucose control and also in the reduction of body weight. The study was conducted by Transition Therapeutics Inc a biopharmaceutical which is based in Toronto Canada.

The study that was undertaken included both diabetic and non diabetic patients. During the study the new drug was used in conjunction with Metformin in all type 2 diabetic patients.

It was also shown that the biggest side effects were, loss of appetite, wight loss which was followed by mild nausea and vomiting. Researchers stated that this is common in these types of drugs.

Transition Therapeutics Inc has secured the rights to TT-40 in 2010 from Eli Lilly and Co. Once the drug has been approved it will be released through Lilly.

New and improved drugs are always welcome as the majority of people do not modify their lifestyle significantly enough no normalise blood sugar levels.

The good news is that for many people who revert to a diet that is free of all processed foods and sugars and maintain this lifestyle, the A1c levels normalise and often their doctor simply takes medication away.